To address this hypothesis, we asked if the same number of Tregs isolated from patients with systemic lupus erythematosus (SLE, one of the diseases that has been treated with low dose IL-2 (16), would have a similar, or less robust response to low dose IL-2 in vitro when compared to Tregs from healthy controls. The gene discussed is IL2; the disease is systemic lupus erythematosus.